Video Latest - ecancer

AlloHCT conditioning intensity in AML in complete remission with residual disease

Dr Christopher Hourigan - National Heart, Lung, and Blood Institute, Bethesda, USA

15 Jun 2019

D-VTd in induction prior to and consolidation after ASCT improves PFS and depth of response with acceptable safety

Prof Philippe Moreau - Chu Nantes, Nantes, France

14 Jun 2019

Intervention for AML patients with MRD can result in improved survival

Dr Christopher Hourigan - Laboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, USA

14 Jun 2019

Novel adoptive cell therapies for acute lymphoblastic leukaemia

Prof Rupert Handgretinger, Director and Chair, Children’s University Hospital and Department of Haematology/Oncology, Tübingen, Germany

24 May 2019

Issues in allogeneic HSCT: Therapeutic options for post-transplant relapse

Prof David Marks - University Hospital Bristol, Bristol, UK

24 May 2019

Optimal use of tyrosine kinase inhibitors as a treatment for Philadelphia chromosome-positive acute lymphoblastic leukaemia

Prof Hervé Dombret, University Paris Diderot, Paris, France

24 May 2019

Advanced HCC: New systemic treatment options

Prof Hesham El-Ghazaly - Ain Shams University, Cairo, Egypt

8 May 2019

How the WIN consortium achieves its goals

Prof Apostolia-Maria Tsimberidou - MD Anderson Cancer Centre, Houston, USA

25 Apr 2019

The translational element of the WIN consortium

Dr Brian Leyland-Jones - WIN Head of Fundraising Committee

25 Apr 2019

Making oncology global with the WIN consortium

Dr Josep Tabernero - Vall d'Hebron Institute of Oncology, Barcelona, Spain

25 Apr 2019

An overview of the WIN consortium

Dr Richard Schilsky - Chief Medical Officer, American Society of Clinical Oncology, USA

25 Apr 2019

The WIN symposium 2019

Prof Razelle Kurzrock - University of California San Diego, San Diego, USA

25 Apr 2019

Video